THR 184

Drug Profile

THR 184

Alternative Names: AA-184; THR-184

Latest Information Update: 05 Apr 2016

Price : $50

At a glance

  • Originator Thrasos Therapeutics
  • Class Anti-inflammatories; Antifibrotics; Apoptosis regulatory proteins; Oligopeptides; Peptides; Small molecules
  • Mechanism of Action Bone morphogenetic protein receptor type I agonists; Bone morphogenetic protein receptor type II agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Acute kidney injury
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Acute kidney injury

Most Recent Events

  • 29 Feb 2016 THR 184 is available for licensing as of 29 Feb 2016
  • 29 Feb 2016 Efficacy and adverse events data from a phase II trial in Acute kidney injury released by Thrasos
  • 29 Feb 2016 Thrasos plans a phase II/III trial in Acute kidney injury (Prevention)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top